Two recent articles [5], [6], demonstrated concomitant over-expression of Myc (cut point >40%) and Bcl2 (cut point >50%) protein by immunohistochemistry (IHC) in DLBCL patients treated with R-CHOP [5], [6] was associated with inferior overall and progression-free survival only when Bcl2 protein was co-expressed with Myc (P<0.001) [5], [6]. This evidence concerns the gene DDIT3 and diffuse large B-cell lymphoma.